Forendo Pharma Ltd, whose lead product is being developed for endometriosis, has signed an exclusive licensing deal with Novartis to use the same technology platform to discover new drugs for chronic liver diseases. The deal, announced on 11 December, is a further validation of the company’s technology for inhibiting a family of enzymes called HSD17B (17-beta-hydroxysteroid dehydregonase) which play a role in multiple diseases.
